Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. - Wikidata - wikimedia - TriplyDB

Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

http://www.wikidata.org/entity/Q35025591

about

Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer MicroRNA-regulated viral vectors for gene therapy The emerging role of viral vectors as vehicles for DMD gene editing Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Prospects for gene transfer for clinical heart failure Cardiovascular gene therapy for myocardial infarction Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure AAV9-mediated gene transfer of desmin ameliorates cardiomyopathy in desmin-deficient mice.Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9 Structure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5 Å Resolution Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins Small and large animal models in cardiac contraction research: advantages and disadvantages Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction.(Pro)renin receptor contributes to regulation of renal epithelial sodium channel.A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart.Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling.A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction.Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver.Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.miR-26a is required for skeletal muscle differentiation and regeneration in mice.Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications.Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery.Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed.Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy Oxidative stress decreases microtubule growth and stability in ventricular myocytes In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.DNA shuffling of adeno-associated virus yields functionally diverse viral progeny

P2860

Q24307681-B4791FAE-4548-417B-A197-E007C25A1176 Q24615809-48366A3E-095E-40E2-9BC2-9CFA3C281AE8 Q26745822-32DF1EA5-FF38-4A24-B804-B4DA8131C7D9 Q26746647-523E6C3D-A512-41FC-89D2-5E1B32E5A25A Q26799437-90F6DA7C-6CAA-4F98-B697-402E541C2915 Q26830145-EE8E2BA7-4CAD-4F7F-B41B-71D0E41F5296 Q27014770-580EEBD9-ECF6-4CEC-9586-F343B2C24D07 Q27318185-AC836816-BA1C-4873-9703-CA050A1B777D Q27318604-684D089D-1D3D-4660-A7F3-CD12C2C6CD2E Q27323272-E2492D62-7883-4981-98BF-09E16BC93FE5 Q27349992-C44C1BEC-4F54-46B4-B943-D6669BAF933F Q27678476-DE39AE52-EB3B-4FFD-AD82-EDEADA181C5C Q27681347-901C726F-B2EA-48AD-9BFA-02B61836EB77 Q27691424-8B8A8DE9-9189-4B21-9B16-52B1E800D053 Q28291547-47F18CFF-357E-4170-8B3D-D0C9A2F1FCA0 Q28579249-0D26C4A2-9CF6-47E3-882D-3F1A2EDBBACD Q28658055-78207124-82BD-43EC-9E82-6DA0ED12FAE0 Q30277247-02E9EBD2-70A9-4282-91BF-060AAD6267B6 Q30277745-4255A1EE-1AED-4491-B628-4EF32BD8271E Q30391624-59D62222-D065-4198-9553-486A0A44A64F Q30413287-CE96EF4B-756A-4B9C-8337-C5F89A397DD9 Q30413864-CFA852C9-1642-495A-A46A-AFF27EC19D11 Q30414524-196D68C9-3A62-4BF9-9708-DB7C9A35C5C7 Q30417032-BA5704C1-369C-46A2-A86E-A3E0DF70BEA8 Q30417445-D145FB7A-6BC4-4BAD-9A66-593720EADEB2 Q30421569-593CE11B-9608-4946-9D31-9F40841EE2FA Q30427066-2BE4297D-D051-4FF5-82CE-86D868822FDC Q30431585-68652EA8-24E5-4308-8BBC-78639FADCF8C Q30483589-FB5D4827-C3CD-4D05-9DB5-C15DAFB6EB60 Q30489689-AE3496B2-288C-4ADA-8B34-05B4682C20AC Q30497589-2B7E3CE2-4B49-43CA-AEB7-4A345BF0E437 Q30500346-5A20CA17-95CE-4932-89AB-82B70845B4FD Q30512833-9AC06FDE-9F39-48B9-830E-8CC7434D6978 Q30515514-D8CAEDF0-AAA7-4BB7-A3A6-B51862CB5A55 Q30519561-C9445F07-C150-4864-B67F-941789B255CF Q30539495-B683B47A-76F0-4DF6-8B7F-BFE7D2051537 Q30541880-399D668C-1C3F-4FA7-B73B-9E089DB58F5B Q30770438-9E239826-AF6B-43A4-850C-E4959E97EBCB Q33327474-50A8E3DB-9E1F-4906-9580-ACD913BD6550 Q33363531-AC0A3511-09F8-439B-8259-D84BD0B431B0

P2860

Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

http://www.wikidata.org/entity/Q35025591

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Robust systemic transduction w ...... sfer superior to that of AAV8.

@ast

Robust systemic transduction w ...... sfer superior to that of AAV8.

@en

type

label

Robust systemic transduction w ...... sfer superior to that of AAV8.

@ast

Robust systemic transduction w ...... sfer superior to that of AAV8.

@en

prefLabel

Robust systemic transduction w ...... sfer superior to that of AAV8.

@ast

Robust systemic transduction w ...... sfer superior to that of AAV8.

@en

P1433

Q35025591-F7C74517-46B5-49F1-9A6B-27DD9461E78E

P1476

Q35025591-0C99555C-1507-44EB-9BE9-E550F56E5D11

P2093

Q35025591-0688468A-031E-4612-9487-4C8DA363A719

Q35025591-3FBB3EC6-7934-4BA3-858E-6F42FAB00D86

Q35025591-6C433301-7B30-4593-9FDC-29B30F39031D

Q35025591-7A4AB4CD-0819-4C8A-861F-ACB3CD3C146A

Q35025591-9E10021D-D5C8-4C20-BBF5-8E2B4B0B129F

Q35025591-A05B31F0-9BD5-4849-B59A-D39E943B3F05

Q35025591-DFCB4C17-98DF-49D3-8D07-BA71ECE4294F

P2860

Q35025591-000404FF-C6BD-4B76-BCA3-1FED9E0C0188

Q35025591-091CD078-0C3D-4E10-86ED-6EC5691BDB0B

Q35025591-0C3AB868-C284-44F7-A85F-950CEF99A94D

Q35025591-16CB5C68-9DD1-42B2-B8C3-ED50D6E863B2

Q35025591-218C8D44-6009-4826-8EC4-F5A3330C0992

Q35025591-21E1F922-3BBC-4794-9603-194E1CA906F1

Q35025591-21E69FBB-C146-4B8C-B048-2D54FB458FF8

Q35025591-287C881D-D93C-4D56-B96E-CEFE16C09660

Q35025591-30BEC1B1-5BE6-485A-BD3D-1FA6ACBC0E6B

Q35025591-33B5637D-725D-41B4-8318-998A8848977D

P304

Q35025591-D0E7A84B-070E-440C-A4DB-309BA3E11FB1

P31

Q35025591-ED19CA80-742E-4D5C-963C-6FBD25A468B2

P356

Q35025591-88FBEC67-68B7-4674-BC1A-5BBB81CCC1A0

P433

Q35025591-5215435C-A4F7-4003-8979-104B85D3499C

P478

Q35025591-571C4FD3-D831-497C-BACC-68EA279CA4E2

P577

Q35025591-C84E5CDE-9677-480A-9DFE-570EDD2F331F

P5875

Q35025591-C9D2BB48-2A5F-4878-A09A-36CEF50F3723

P698

Q35025591-CC6D58A3-4C8B-4FD4-BC18-BF80FD199B86

P932

Q35025591-5D93909D-D5FC-458B-B199-698069FBF871

P356

J.YMTHE.2006.03.014

P1433

Molecular Therapy

P1476

Robust systemic transduction w ...... sfer superior to that of AAV8.

@en

P2093

Charles F Mctiernan

http://www.w3.org/2001/XMLSchema#string

Gregory A Gibson

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Nakai

http://www.w3.org/2001/XMLSchema#string

Katsuya Inagaki

http://www.w3.org/2001/XMLSchema#string

Mark A Kay

http://www.w3.org/2001/XMLSchema#string

Sally Fuess

http://www.w3.org/2001/XMLSchema#string

Theresa A Storm

http://www.w3.org/2001/XMLSchema#string

P2860

Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue.

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Cloning and characterization of adeno-associated virus type 5.

Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver.

Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Clades of Adeno-associated viruses are widely disseminated in human tissues.

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMTHE.2006.03.014

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7069107

http://www.w3.org/2001/XMLSchema#string

P698

16713360

http://www.w3.org/2001/XMLSchema#string

P932

1564441

http://www.w3.org/2001/XMLSchema#string